Navigation Links
Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
Date:7/28/2008

PITTSBURGH, July 28 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nisoldipine Extended-release (ER) Tablets, 20 mg, 30 mg and 40 mg.

Nisoldipine ER Tablets, indicated for the treatment of hypertension, are the generic version of Sciele Pharma's Sular(R) ER Tablets, which had annual U.S. sales of approximately $94 million for the 12 months ending March 31, 2008, for these three strengths. Mylan's Nisoldipine ER, which is being shipped immediately, is the first generic version of Sular ER to be introduced in the United States.

Currently, Mylan has 93 ANDAs pending FDA approval, 21 of which are potential first-to-file opportunities.

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
10. Novozymes Launches Enzyme to Reduce Acrylamide in Food
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... second contract from the U.S. Environmental Protection Agency ... company’s expertise in developmental toxicity models, including tests ... on neuron formation and the formation of connections ... function. Inhibition of neurodifferentiation and synapse formation by ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... 20, 2011 Masimo (Nasdaq: ... the clinical accuracy and value of its noninvasive and ... week at the Society of Critical Care Medicine ... The largest multi-professional critical care event of the year, ...
... Reportlinker.com announces that a new market research report ... Hospital Computer Tomography (CT) Census ... the most comprehensive European market report on the ... Mammography, R&F, Angiography, CT, MRI,) and radiology IT ...
... GPRO ) announced today that the Company will ... on Tuesday, February 15, 2011 at approximately 4:00 p.m. Eastern ... call with management at 4:30 p.m. ET.   ... accessed on the investors section of the Company,s web site ...
Cached Biology Technology:New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 2New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 3New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 4New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 5Reportlinker Adds Hospital Computer Tomography (CT) Census 2Reportlinker Adds Hospital Computer Tomography (CT) Census 3Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call 2
(Date:7/30/2014)... The use of iodine-125 (125I) in cancer treatment ... dorsal root ganglia are critical for neural transmission ... Tengda Zhang and colleagues from Institute of Radiation ... that 125I could be implanted into rat dorsal ... pain. 125I seeds with different radioactivity (0, 14.8, ...
(Date:7/30/2014)... July 30, 2014 The Nano-Bio Manufacturing ... States Air Force Research Laboratory (AFRL), has awarded ... Binghamton University to develop electronics and ... The $425,000 project, with contributions from the University ... Electronics, Inc. ( Endicott, N.Y. ), ...
(Date:7/29/2014)... optical methods and applications for imaging and manipulation of ... neurosciences were the inspiration behind Neurophotonics , a ... for optics and photonics. , The first issue coincides ... United States, and a special section features articles that ... the impact that optics and photonics will have on ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... poorest regions could face severe crop losses in the next ... study by researchers at Stanford Universitys Program on Food Security ... in the Feb. 1 issue of the journal Science. ... agriculture for their livelihoods, said lead author David Lobell, a ...
... has some amazing properties. It is the only natural substance ... within the range of natural Earth temperatures. Its solid ... why ice floats. It can absorb a great deal of ... it move through roots and capillaries vital to maintaining ...
... process for medical devices does not involve the same ... change in order to improve health outcomes, say researchers ... The UCSF team analyzes the problem and proposes ... the January 2008 issue of the Journal of General ...
Cached Biology News:Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 4ASU professor helps solve mystery of glassy water 2ASU professor helps solve mystery of glassy water 3Analysis calls for medical device information to better serve patients and doctors 2Analysis calls for medical device information to better serve patients and doctors 3
...
... Kit is an advanced system for isolating DNA from ... be used directly for any downstream application. ... to use in 56 minutes Low melting point ... and TBE gels No specialised equipment required ...
... Spin Columns provide a rapid and simple method ... bp to 10 kb) from stained agarose gels ... excised from an agarose gel and loaded into ... the column are a series of membranes and ...
... Kit has been designed for recovery of DNA from ... Features Ultra fast protocol: DNA is ready ... are easy to resuspend Bead uniformity prevents shearing ... (suitable for PCR) DNA is eluted into sterile ...
Biology Products: